Tradestie Institutional Equity Comparison Engine

MBX vs XOMA โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

MBX Overall Edge

MBX Captures Institutional Edge (3โ€“1 Pillars ยท 3โ€“7 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to MBX Biosciences, Inc. Common Stock (MBX) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while XOMA counters with relative strength in Valuation. Fundamentally, MBX trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus XOMA at 21.5x Forward P/E and -3.9% operating margin (-22.6% YoY). In options structure, MBX sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro) against XOMA sits in UNCLASSIFIED (100th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner XOMA
MBX N/M vs XOMA 21.5x Fwd P/E
Growth & Margin Winner MBX
Op Margin 0.0% vs -3.9% ยท YoY +0.0% vs -22.6%
Momentum & Technical Winner MBX
1Y +122.4% vs +44.0% ยท 52W Pos 62% vs 78%
Options & Structure Winner MBX
UNCLASSIFIED (<1st %ile IV) vs UNCLASSIFIED (100th %ile IV)
MBX NASDAQ
MBX Biosciences, Inc. Common Stock
Pharmaceutical Preparations
$53.54
-4.29% 1D
Market Cap $2.7B
1M Return +7.92%
1Y Return +122.43%
Forward P/E N/M
Unified AI Score
44.9 / 100 HOLD
Tech 42.0 Fund 47.0 Flow 50.0 Mom 54.0
XOMA NASDAQ
XOMA Royalty Corporation Common Stock
Pharmaceutical Preparations
$40.17
-9.16% 1D
Market Cap $781.8M
1M Return -3.81%
1Y Return +43.98%
Forward P/E 21.5x
Unified AI Score
55.8 / 100 HOLD
Tech 40.0 Fund 52.0 Flow 50.0 Mom 64.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: MBX +122.43% XOMA +43.98% Spread: +124.84 pp (MBX Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
MBX TTM Op. Margin: 0.0% XOMA TTM Op. Margin: -3.9%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MBX vs XOMA. Trailing 12-month operating profitability (MBX 0.0% vs XOMA -3.9%) and valuation multiples (MBX N/M vs XOMA 21.5x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: MBX (3) vs XOMA (7)
Institutional Metric MBX XOMA Criterion Row Winner
Market Capitalization Scale $2.7B $781.8M Larger Scale MBX
Trailing P/E Ratio Valuation N/M 28.2x Lower Multiple XOMA
Forward P/E Ratio Valuation N/M 21.5x Lower Multiple XOMA
Revenue Growth (YoY) Growth +0.0% -22.6% Higher Growth MBX
Operating Margin (TTM) Profitability 0.0% -3.9% Higher Margin MBX
Net Profit Margin Profitability 0.0% 69.6% Higher Margin XOMA
Return on Equity (ROE) Capital Efficiency -33.7% 34.2% Higher ROE XOMA
52-Week Range Position Momentum 62% ($23โ€“$73) 78% ($22โ€“$45) Stronger Trend XOMA
Beta / 30D Volatility Risk Regime 1.58ฮฒ ยท 66% Vol 0.68ฮฒ ยท 37% Vol Lower Realized Risk XOMA
Unified Institutional Score Composite Signal 44.9 / 100 (HOLD) 55.8 / 100 (HOLD) Higher Composite XOMA

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full MBX vs XOMA Buy Guide
MBX UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile <1st %ile
IV Regime Compressed (<25th %ile)
Live MBX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
XOMA UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 100th %ile
IV Regime Extreme (>80th %ile)
Live XOMA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither MBX nor XOMA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.